NCT03691714 2023-12-08
Durvalumab (MEDI4736) With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
University of Cincinnati
Phase 2 Unknown
University of Cincinnati
Jules Bordet Institute
University of California, San Diego
Institut Català d'Oncologia
Gustave Roussy, Cancer Campus, Grand Paris
Azienda Ospedaliero-Universitaria Careggi